Flavoxate Hydrochloride
RxNorm 1095229· FLAVOXATE HYDROCHLORIDE· ORAL
PuraCap Laboratories LLC dba Blu Pharmaceuticals
Indications and usage
INDICATIONS AND USAGE Flavoxate hydrochloride tablets are indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis. Flavoxate hydrochloride tablets are not indicated for definitive treatment, but are compatible with drugs used for the treatment of urinary tract infections.
Dosage and administration
DOSAGE AND ADMINISTRATION Adults and children over 12 years of age One or two 100 mg tablets 3 or 4 times a day. With improvement of symptoms, the dose may be reduced. This drug cannot be recommended for infants and children under 12 years of age because safety and efficacy have not been demonstrated in this age group.
Warnings
WARNINGS Flavoxate hydrochloride should be given cautiously in patients with suspected glaucoma.
Contraindications
CONTRAINDICATIONS Flavoxate hydrochloride is contraindicated in patients who have any of the following obstructive conditions: pyloric or duodenal obstruction, obstructive intestinal lesions or ileus, achalasia, gastrointestinal hemorrhage and obstructive uropathies of the lower urinary tract.
Pregnancy
Pregnancy Teratogenic Effects-Pregnancy Category B Reproduction studies have been performed in rats and rabbits at doses up to 34 times the human dose and revealed no evidence of impaired fertility or harm to the fetus due to flavoxate hydrochloride. There are, however, no well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Nursing mothers
Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when flavoxate hydrochloride is administered to a nursing woman.
Adverse events
Most frequently reported events (FDA FAERS). Report frequency does not imply causation.
- pyrexia13
- mucosal inflammation10
- pruritus9
- hepatic function abnormal8
- toxic epidermal necrolysis8
- pneumonia7
- aspartate aminotransferase increased6
- exposed bone in jaw6
- oral disorder6
- oroantral fistula6
- osteonecrosis of jaw6
- alanine aminotransferase increased5
- blood lactate dehydrogenase increased5
- decreased appetite5
- lip erosion5
- nausea5
Adverse reactions (label)
ADVERSE REACTIONS The following adverse reactions have been observed, but there are not enough data to support an estimate of their frequency. Gastrointestinal: Nausea, vomiting, dry mouth. CNS: Vertigo, headache, mental confusion, especially in the elderly, drowsiness, nervousness. Hematologic: Leukopenia (one case which was reversible upon discontinuation of the drug). Cardiovascular: Tachycardia and palpitation. Allergic : Urticaria and other dermatoses, eosinophilia and hyperpyrexia. Ophthalmic: Increased ocular tension, blurred vision, disturbance in eye accommodation. Renal: Dysuria.
View more: Full FDA label on DailyMed →Label effective 20251211